Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.
Take me to the complete story . . .
The Latest on: Cell replacement therapy
[google_news title=”” keyword=”Cell replacement therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cell replacement therapy
- Deaf toddler can hear after gene therapy world firston May 8, 2024 at 10:03 pm
A deaf toddler is now able to hear after becoming the first patient in the world to receive a new gene therapy.
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Resultson May 8, 2024 at 9:01 am
stem cell-derived investigational therapy for the treatment of T1D, which incorporates gene edits that aim to make cells hypoimmune and enhance cell fitness. This immune-evasive cell replacement ...
- Eighth Circuit addresses Constitutional Rights of Transgender Inmate in Lawsuit Against Prison Officialson May 8, 2024 at 8:26 am
The U.S. Court of Appeals for the Eighth Circuit recently held that individual defendants in a Section 1983 lawsuit brought by a transgender inmate were entitled to qualified immunity on some, but not ...
- Buy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA Patientson May 8, 2024 at 8:01 am
The clinical data presented at the Retinal Cell & Gene Therapy Innovation Summit highlighted the treatment ... The company’s programs are based on two core proprietary technology platforms: cell ...
- Repurposed cancer drug to help replace insulin therapy for diabeteson May 7, 2024 at 6:14 am
A drug used for the treatment of pancreatic cancer can be repurposed to replace insulin therapy among people with diabetes, scientists have found.
- Repurposed cancer drug could treat diabetes by nudging pancreatic acinar cells to produce insulinon May 6, 2024 at 2:11 pm
University of Pittsburgh researchers Dr. Farzad Esni, Ph.D., and Jing Hu, Ph.D., did an experiment in mice where they deleted one of two copies of the gene encoding an enzyme called focal adhesion ...
- The tale of two companies: One viral vector partner for every stage of gene therapy developmenton May 6, 2024 at 1:00 am
With a goal of developing a Parkin gene replacement therapy, NysnoBio is in the early ... In December 2023, the company received FDA approval for its one-time gene therapy for sickle cell disease.
- MRNA vaccine effective in treating glioblastoma brain cancer in small trialon May 2, 2024 at 9:24 am
An experimental cancer vaccine can quickly reprogram a person's immune system to attack glioblastoma, the most aggressive and lethal form of brain cancer, a small, preliminary study has found.
- Somite Therapeutics to Present at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)on May 1, 2024 at 3:13 am
[[To comply with academic institution guidelines, the founders' academic affiliations and roles are listed only at the end of the statement.]] BOSTON, May 1, 2024 /PRNewswire/ -- Somite Therapeutics, ...
- Study introduces improved way to grow cells that give rise to kidney's filtration systemon April 30, 2024 at 8:00 am
In a study published in Cell Stem Cell, USC scientists report significant progress in cultivating nephron progenitor cells (NPCs), the cells destined to form the kidney's filtration system, the ...
via Bing News
